Terms: = Leukemia AND ABL1, p150, 25, ENSG00000097007, P00519, v-abl, bcr/abl, JTK7, c-ABL, ABL, BCR-ABL AND Clinical Outcome
331 results:
1. [The value of minimal residual disease and IKZF1 deletion for predicting prognosis in adult patients with B-cell acute lymphoblastic leukemia].
Deng SY; Ou JW; Huang ZC; Chen JJ; Cai ZH; Liu QF; Zhou HS
Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):257-263. PubMed ID: 38716597
[No Abstract] [Full Text] [Related]
2. A Comprehensive Metabolism-Related Gene Signature Predicts the Survival of Patients with Acute Myeloid leukemia.
Zhai Y; Shen H; Wei H
Genes (Basel); 2023 Dec; 15(1):. PubMed ID: 38254953
[TBL] [Abstract] [Full Text] [Related]
3. bcr::abl1 kinase domain mutation testing and clinical outcome in a nationwide chronic myeloid leukemia patient population.
Kockerols C; Valk PJM; Blijlevens NMA; Cornelissen JJ; Dinmohamed AG; Geelen I; Hoogendoorn M; Janssen JJWM; Daenen LGM; Reijden BAV; Westerweel PE
Eur J Haematol; 2023 Dec; 111(6):938-945. PubMed ID: 37731314
[TBL] [Abstract] [Full Text] [Related]
4. [Efficacy and safety of secondary allogeneic hematopoietic stem cell transplantation in 70 patients with recurrent hematologic malignancies after transplantation].
Han TT; Liu Y; Chen Y; Zhang YY; Fu HX; Yan CH; Mo XD; Wang FR; Wang JZ; Han W; Chen YY; Chen H; Sun YQ; Cheng YF; Wang Y; Zhang XH; Huang XJ; Xu LP
Zhonghua Xue Ye Xue Za Zhi; 2023 Jun; 44(6):458-464. PubMed ID: 37550200
[No Abstract] [Full Text] [Related]
5. Dual inhibition of STAT3 and STAT5 may overcome imatinib resistance in chronic myeloid leukemia.
Yin L; Xu J; Wu W; Niu M; Li Z; Zhu F; Xu K
Hematology; 2023 Dec; 28(1):2224625. PubMed ID: 37345979
[TBL] [Abstract] [Full Text] [Related]
6. Leukapheresis and Tisagenlecleucel Manufacturing outcomes in Patients Age <3 Years with Relapsed/Refractory Acute Lymphoblastic leukemia.
Fong D; Tiwari R; Acker C; Clough L; Willert J
Transplant Cell Ther; 2023 Sep; 29(9):579.e1-579.e10. PubMed ID: 37311511
[TBL] [Abstract] [Full Text] [Related]
7. [Current management and new treatment strategies of chronic myeloid leukemia].
Crysandt M; Brümmendorf TH
Dtsch Med Wochenschr; 2023 Jun; 148(12):744-751. PubMed ID: 37257476
[TBL] [Abstract] [Full Text] [Related]
8. Estimating prognostic relevant cutoff values for a multiplex PCR detecting bcr::abl1 in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy in resource-limited settings.
Hailu S; Kinde S; Cross M; Tsegaye A; Kelemu T; Seifu D; Alemayehu D; Tarekegn A; Jabessa G; Abeje D; Abebe M; Sherif A; Tadesse F; Platzbecker U; Howe R; Gebremedhin A
Ann Hematol; 2023 Jul; 102(7):1723-1729. PubMed ID: 37212909
[TBL] [Abstract] [Full Text] [Related]
9. Characterization of the input material quality for the production of tisagenlecleucel by multiparameter flow cytometry and its relation to the clinical outcome.
Štach M; Pytlík R; Šmilauerová K; Rychlá J; Mucha M; Musil J; Koladiya A; Nemec M; Petráčková M; Kaštánková I; Pecherková P; Šrámková L; Polgárová K; Trněný M; Lesný P; Vydra J; Otáhal P
Pathol Oncol Res; 2023; 29():1610914. PubMed ID: 37151356
[TBL] [Abstract] [Full Text] [Related]
10. Implication of Dynamin-2 (DNM2) Mutations in Adult T-cell Acute Lymphoblastic leukemia.
Sobh M; Aref S; Al Agdar M; El Zafrany M; El-Sokkary AMA
Asian Pac J Cancer Prev; 2023 Apr; 24(4):1257-1264. PubMed ID: 37116148
[TBL] [Abstract] [Full Text] [Related]
11. Somatic Exonic Deletions in RUNX1 Constitutes a Novel Recurrent Genomic Abnormality in Acute Myeloid leukemia.
Eriksson A; Engvall M; Mathot L; Österroos A; Rippin M; Cavelier L; Ladenvall C; Baliakas P
Clin Cancer Res; 2023 Aug; 29(15):2826-2834. PubMed ID: 37022349
[TBL] [Abstract] [Full Text] [Related]
12. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study.
Lazzarotto D; Tanasi I; Vitale A; Piccini M; Dargenio M; Giglio F; Forghieri F; Fracchiolla N; Cerrano M; Todisco E; Papayannidis C; Leoncin M; Defina M; Guolo F; Pasciolla C; Delia M; Chiusolo P; Mulè A; Candoni A; Bonifacio M; Pizzolo G; Foà R
Ann Hematol; 2023 May; 102(5):1099-1109. PubMed ID: 36959485
[TBL] [Abstract] [Full Text] [Related]
13. SAMHD1 single nucleotide polymorphisms impact outcome in children with newly diagnosed acute myeloid leukemia.
Marrero RJ; Cao X; Wu H; Elsayed AH; Klco JM; Ribeiro RC; Rubnitz JE; Ma X; Meshinchi S; Aplenc R; Kolb EA; Ries RE; Alonzo TA; Pounds SB; Lamba JK
Blood Adv; 2023 Jun; 7(11):2538-2550. PubMed ID: 36689724
[TBL] [Abstract] [Full Text] [Related]
14. Stratification and therapeutic potential of ELL in cytogenetic normal acute myeloid leukemia.
Zha J; Zhong M; Pan G; Chen Q; Jiang Y; Lai Q; Tan J; Zhou H; Wu H; Xu B
Gene; 2023 Mar; 856():147110. PubMed ID: 36543308
[TBL] [Abstract] [Full Text] [Related]
15. Association of Minimal Residual Disease by a Single-Tube 8-Color Flow Cytometric Analysis With clinical outcome in Adult B-Cell Acute Lymphoblastic leukemia: A Real-World Study Based on 486 Patients.
Liao H; Jiang N; Yang Y; Zhang X; Chen J; Lai H; Zheng Q
Arch Pathol Lab Med; 2023 Oct; 147(10):1186-1195. PubMed ID: 36508349
[TBL] [Abstract] [Full Text] [Related]
16. Lack of FLT3-ITD in Tunisian childhood acute lymphoblastic leukemia.
Frikha R; Abdellaoui N; Kassar O; Rebai T
Afr Health Sci; 2022 Jun; 22(2):318-322. PubMed ID: 36407352
[TBL] [Abstract] [Full Text] [Related]
17. B-Lymphoid Blast Phase-Chronic Myeloid leukemia: Current Therapeutics.
Yohannan B; George B
Int J Mol Sci; 2022 Oct; 23(19):. PubMed ID: 36233138
[TBL] [Abstract] [Full Text] [Related]
18. Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid leukemia: Results of a Systematic Review and Meta-Analysis.
Kharfan-Dabaja MA; Reljic T; Yassine F; Nishihori T; Kumar A; Tawk MM; Keller K; Ayala E; Savani B; Mohty M; Aljurf M; Saber W
Transplant Cell Ther; 2022 Nov; 28(11):767.e1-767.e11. PubMed ID: 35970301
[TBL] [Abstract] [Full Text] [Related]
19. [Prognostic factors of autologous hematopoietic stem cell transplantation in intermediate-risk acute myeloid leukemia patients with minimal residual disease negativity].
Lian JY; Ye PP; Cao JJ; Chen D; Wang TT; Si T; Yuan JJ; Lu Y
Zhonghua Nei Ke Za Zhi; 2022 Jun; 61(6):673-677. PubMed ID: 35673748
[TBL] [Abstract] [Full Text] [Related]
20. Molecular characterization and clinical outcome of B-cell precursor acute lymphoblastic leukemia with IG-MYC rearrangement.
Bomken S; Enshaei A; Schwalbe EC; Mikulasova A; Dai Y; Zaka M; Fung KTM; Bashton M; Lim H; Jones L; Karataraki N; Winterman E; Ashby C; Attarbaschi A; Bertrand Y; Bradtke J; Buldini B; Burke GAA; Cazzaniga G; Gohring G; De Groot-Kruseman HA; Haferlach C; Nigro LL; Parihar M; Plesa A; Seaford E; Sonneveld E; Strehl S; Van der Velden VHJ; Rand V; Hunger SP; Harrison CJ; Bacon CM; Van Delft FW; Loh ML; Moppett J; Vormoor J; Walker BA; Moorman AV; Russell LJ
Haematologica; 2023 Mar; 108(3):717-731. PubMed ID: 35484682
[TBL] [Abstract] [Full Text] [Related]
[Next]
